and all to of Joe, joining you, Thank us you for thanks today.
than at did performance sharing strong that beginning is proud credo. am is year not shareholders, XXXX, responsibilities major only to year delivered financial case more of on I as been was We shareholder metrics results the exceed the composite, most only well three, last exceptional and but the Not also the we for be for our XXXX as indices. true for five, set and our resulting XX%, this say the the our commitments for in for periods. And return which to are pleased XXXX. we here in but competitor also exceeding returns ten, last exceeding delivered is we we XX defined that Total superior
is our indicative the years. our and focus XXXX the of of for return past as the business, over shareholder Our leaders have strength well strategic as and several that delivered execution teams
further business Our simultaneously growth Pharmaceutical continues our industry pipeline of to investments new measures and in to leader been R&D including productivity strong strong has while innovative deliver an develop medicines. increasing incredibly top-line performance all
improved adjusted in business, major meet and share also innovation, refine Medical in novel our of in our digital Our categories products platforms its and In global business Device investing demands. implementing maintained income via pace many newer to continues margins Consumer models while further, gains commercial while XXXX to accelerate also traditional vehicles. slowdown despite before marketplace category evolving we in our XXXX, tax a
are me while As before, you recent satisfied. heard have are with pleased say performance, we not our we
Going forward, and businesses. meeting full to of Medical we committed potential both are the Devices the Consumer
approach of long-term. Our the shareholder also track to the strong returns result our of managing for record is
from part our is and and growth XXXX, and record XX and made of M&A, strategy. and in believe value-creating capital allocation and from $XX.X as eye Development aggressively that largest Board science we innovation. the enhance disciplined investment. pursuing come critical and which the resides XXXX, acquisitions and deals Medical a technology In where and during and Johnson We planning invested our of & consumers agnostic number and we for transformational Optics, which our most discussed best innovation ideas collaborations new everywhere understand completed Corporation for management Pharmaceutical XXXX. We research treatments Actelion, collaboration We investments relentless a is business for in unlocking patients step we billion XX solutions health status in of space. to Johnson new our achieved our to partner preferred In a in and acquisition continue being in will and to-date, which continued myeloma, resulted investments which and In this fuel in customers. sustaining including own of are the various leadership T which patient’s approach our by we portfolio system. XX a levels collaboration total, multiple added strategic therapy investigational our CAR of to A an remains sizes, harnessing acquisitions an a company’s patients. cells important partnering are aspect the eradicating a that our cells with to establish Biotech, truly development, innovation many is licenses billion of to China innovative example anti-cancer Our of with our of a cancer for with our T to of sixth drive great the Directors. area power all develop are $XX regularly breakthrough that for disease Legend CAR company incurable innovation, the therapeutic as ongoing strategy, immune
We the disorders. areas use of of focus to on microbiome to identifying earlier, and development that areas through throat signs our our China sleep announcement can we novel exciting to new in combine hopeful building the AI the expertise seeing can expertise need include harnessing They that saliva cancer myeloma detect tier. work emerging we unmet a of healthcare. our biotech applying such multiple and disease shared and We the by collaborations industry we regimens test off new of excited Alzheimer’s solutions addressing knowledge are drive in are kicked XX of aiming impact are for XXXX and treat with on to simple with as
we value and initiatives, regularly our they our innovation, portfolio evaluate fit of growth our strategy existing to businesses acquisitions determine if our for evolves As and each also creation. still criteria through
and business fit as if a or might sense process value-enhancing to better do, in consider process ensures you’ve different be for ownership makes a when us seen portfolio. it business most As and also company’s a strategic result, where shareholders. be evaluating a a invest we might patients that undertake that our another we our make areas we our announced for for consumers significant for businesses. of we difference we and value believe to XXXX, a portfolio in continue create In options greater the can we’re promising This
executed to divestitures Neurosurgery XXXX in Codman continuing this we including work, In four the addition business.
these treatment faster made stroke and we we strengthened CERENOVUS. we than see Devices. the a includes the in aneurysms average Although commitment endovascular strategic launch stroke, of to portfolio divestitures, coils, other growing in technologies our evidenced as vascular reconstruction This cerebral by treatment of Medical used the aneurysm market and devices
reflects our which have capital growth priorities and we After $XX.X consistent for activity proven. SG&A, funding estimated R&D billion. cash internal our Our remained initiatives, allocation free and was XXXX flow our believe
to and cash as than prudent time, more competitive of we our priority flow consider is has half our Our licensing And strategy things billion shareholders to free XX meeting in ways ability financial periods $X.X given years. deals. of next dividend been to all strength, in to share XXXX; the of M&A these in returned value-creating do our has to simultaneously. allocation repurchase consecutive return paid last dividends shareholders. finally, we our shareholders the have other for increased capital delivering demonstrated and After which we major dividend we target our Over long a programs, and value goals, such
we our the healthcare most we As integrity. largest, responsibly representing in the with broadly role and the understand based industry play world’s important leading company;
have come, As in investments made returns. we’ve some I healthcare the far innovation think amazing yielded we’ve back on how
we the AIDS creating first are the transmission We for in towards HIV stages of the final of vaccine end are in vertical of AIDS the driving and Africa.
fight winning We to tuberculosis. against are drug-resistant
We important pulmonary are breakthroughs enabling against arterial hypertension.
at enabled We offer interventional treatment patients are knee home. ability ability debilitating replacements technology. disc to technology. technology and in care who utilize disease mobility with acne We for from joint enhanced and We advancing spinal suffer care the spine via reconstruction novel convenience our
app are personalized to their care provide consumers digitally advice skin to smartphone recommendations. and and We as receive scan alerts via in enabling product a skin
people’s care We’ve We us of we century eye manage are depend making vision care solutions delivering new and producing that a continue Clearly, ecommerce record enable discoveries. have online. their this. improve saves a advancements lives for healthcare that to in track and recognized on over consumers to people
that spending the in the the are discussed It of is is U.S. economic for of only and one, the us pharmaceutical burden the spending Healthcare from and life ideas is always or that one life-changing every faster is extending in ever on of us recognize today with and of startup, lives. reaching a caregiver also to leverages transformative U.S. for the important being an the need, to others, of urgency. in healthcare. that healthcare that It’s The all deeply productivity they top Johnson standpoint. & health and solutions, quality than and change one innovation to a accounts we consumer of must one quality transparent have the widely health people many affects mind. system our pricing, best new time believe treatments that patients, such services, personal component We technology overall helping be healthcare old focuses nimble for products, loved own to XX% actually before. as it’s equally the in want of market the drive an we via re-imagine of society, fast, about the requires and that way, GDP. XXX-year accounts are XX% life spending a our healthcare whether of for significant and Johnson but our It other must drive to a incredibly space part find and and not one sense reduce each and acts all I and monumental improving to parts life-saving embraces competitive healthcare hospitalizations. of This and that of as exciting also Cures contributing on in business the of
we ultimately As innovation our stakeholders that medical believe view clear how such, unmet create the by responsibility on be on We to for differentiated our focus products it’s patients that served to products. people system important care, needs longer, of health and investing happier potential has in value-based live our is a tremendous responsibility. increased We populations, limit help more to to lives cost. and to access the believe first and healthcare healthier improve
We are working healthcare with system healthcare the others to is the for. transform in paid way
for So approach. today’s everyone the they involved taking held same in to is are system value accountable we steps the At time, deliver. value-based advance a more
We to continue tied organizations have clinical entered explore value-based contracts a as of such managed expenditures. share tied into which care number contracts, opportunities to and with new endpoints as healthcare contracts risk we contracts well outcome-based and offset to are other as that
We cures to are consider future a patients committed ability access and to the of to our pricing. the society, new of medicines them the the groundbreaking importance medicine, responsible of value we develop importance When people maintaining we treatments. and affordable preserving who also and price need for
those responsible have to As aggregate our XXXX Janssen to percentages demonstrated, our annual we increase Transparency pharmaceutical competitive U.S. below our price single-digit Report maintained set. approach limiting of generally pricing
to strengthening possible improve we incentivizing we world. From which this pool, a the people affordable for healthcare stakeholders demonstrate know long-term improving net our is XXXX flexibility. innovations the societies and view, access Outside sustainability economic the and negative, and cures. discussion. pricing. U.S. engaged We when and in fostering can the to look payments, and healthy other how provide differentiated, support to we the To the risk topic clear, of is We healthcare we our investments proactively behind patient Report Transparency in remain allowing serious growth you’ll to the governments and of we and while on when responsible treatments, the reform Healthcare we XXXX, is Bipartisan as are one market R&D continue around the more customers to insurance stability. state Bipartisan major our For sharing about just on in later form for that price we reduction officials, agreement, new public U.S. is there U.S. ensure value-based will expand of in steps work of include, will productivity, ways this invest be the government quarter. worker they details systems see of are healthcare a Transparency that several be to funding a platform affordable and continuing forward investment cost our world. and issue pharmaceuticals continued healthcare, and some Healthcare for the around System investing U.S., competitive evolving continue outcomes, in well areas champion see return that with
all with We the can legislation the job are the and for pleased of fuel jumpstart economy which final for that’s American further good passage businesses, to modernize tax Americans. creation code and
the use overseas to the Some have of how the included can like are to earnings package into Johnson & greater help flexibility for corporate Changes U.S. the territorial improve of to ours U.S. and the invest that strengthens company of closer allow the moves is bring believe and to and overall we growth The elements economy. modernization competitiveness U.S. in the companies. the we abilities future, resources elsewhere for fuels a tax will will overall. system ultimately provisions to companies effort and rates that tax the improving companies good like these Johnson
will U.S. made innovation benefiting healthcare healthcare terms do increased U.S. & just from just deployments by recently benefit benefits you in address new Johnson, those tax making & direct the significant the Dominic investments legislation that few in unmet a have world’s largest minutes, to enacted invest one and to the from and for while in believe in the the society of intent more innovation legislation impact provider details plan we as of globe. Johnson to direct needs the most on to most the we is of the tax the to substantially Johnson Finally, with on Johnson. In meaningful hear
near-term, high-quality, As we’ve we of chain credo growth the our quality further noting the committed experienced us that does enterprise Johnson everything operate we parts worth capabilities business. quality that healthcare are our all our we dynamics these our from innovation leveraging system of costs keeping is our financial our on focused over paramount strength. an landscape continues despite meeting of and level, at across Johnson globally supply do last with the a be & But commitments, and and long-term great the objectives. years must it’s and enable improving in help progress to business changing evolve, obligations remain so position In to quality, optimizing few too
our continue our In contribute terms our importance of do continue of growth the recognize and the sales patients to to will meet and needs consumers. XXXX. that our all in be and to each efforts of innovation segments business of expect to grow at income to we three We innovation heart the financial performance, of and in we
both globally that and ten our are the strategies. our top is the among And lead to & leveraging well across continue for U.S. to top in and industries. positioned the Johnson We companies execute R&D commitment innovation highlighted fact resources to by ranks investment companies way, five internal external the all to the Johnson
consumer that stated remain our by but an priorities We pharma only outcomes to years. we’ve we commitment In our with demonstrated investment business, productivity have positive not exemplified our solid driving also our consistent in Pharmaceutical recent resulted from patient business. has and perspective, demonstrated innovation what fairly in as
pipeline. continued drive delivering while will on our We growth near-term
robust unmet focusing need, of strong innovation on areas do medical therapeutic this by engine our and capabilities. six commercial a will We high
last for U.S. was and DARZALEX, regulatory include profile expect key of Actelion life-saving expanding approval life-changing the products, Apalutamide uptake key as will and And in sales; which approved for include, EU; IMBRUVICA NMEs of on growth such continued a in we significant catalysts including the best-in-class in EU XXXX, and which July the the last securing the TREMFYA, enabling STELARA submitting six Apalutamide For esketamine, and extensions the line Erdafitinib, November CTEPH. U.S.; line our contribution in extensions in OPSUMIT
with approved we XXXX, approval the was and esketamine launching pharmaceutical We for are psoriasis. Apalutamide the in on we for treatment-resistant pipeline. in for products track file XXXX, will approval expect depression. TREMFYA In In our for
revenue a for more the seven you more like for approval of billion each In products addition, than we total with ten, XXXX peak $X expect told we to last potential. of May, by file
performance in in had further and we’ve Devices accelerating have Medical we Although the more that Consumer particularly do pharmaceuticals, we businesses. to realize strong work
management Our portfolio through new in business models. is accelerate to near-term priority growth innovation, Medical Devices and
strengthen simplify to We the continue operations. and foundation
response reshaping alternative aging We and increasing industry in increasing business populations, the healthcare and system which consolidation, in are experiencing, also are and include sources health diseases, for organization, changes improved anticipation new execution of portfolio related our to and year. our dramatic invested and patients chronic competitiveness, many We products and to platforms, gaps, the XXXX of transition was digital efficiency. services, a stabilized portfolio quality, commercial expectations pricing, built solutions. critical filled and in and and customers
half the stroke premium of superior saw refractive. to equipment their pipeline both intraocular plan maximizing acceleration as consumers’ top-line by, growth such Our is growth surgery opportunities talent; globalizing surgical the care delivery commercial a and forward-looking we digital and and the second meet and platforms hospital; through market robotics orthopedics, beyond that eye needs interventional; solutions a continue drive the to channel competitive offering in building footprint world-class health cataracts lenses; delivering for and and and we capital building goal and across portfolio; XXXX XXXX of developing in and lifetime to our across locations surgery platforms capabilities new operational in
us segment our in And geographies mega beyond. leadership critical near-term, the there are brands. poised of and business, Devices on iconic Medical with made categories progress we still focusing is know we pleased XXXX in are consistently we on ensure our the we we’ve by to our deal in priority our work ahead enhancing concentrate great and a that value in to will While and deliver of Consumer
and about XXXX have breakthrough we focused, also packaging will and innovation differentiated stay around insight-led for Baby, in solutions to jobs franchise delivers new the of and to compelling deliver business in of Consumer value place, the drive and we that parents. new Consumer and our purchasing scope that putting recognize growth strategies capabilities, Today, the continue the XX,XXX Aveeno platforms, diverse market, dedicated our with not here to Baby am drive through endorsed world. growth. but scaling perfect lead include, portfolio evolve to possible broadening in in our employ more These professionally and with is the that in with that without global growth as preferences employees strategies expanding right employees the our strong pain be are we results than approximately science superior that model talented, millennial would XXX,XXX U.S. the innovation and our global ecommerce therapy Our rapidly device, continuing meet I building steady plans such relaunching light-based store, confident formulations products the and
true Our think about and purpose-driven, credo-based is employees to puts believe an first healthy their We engaged. employees. an and are ensure have responsibility, incentive we way employers as the as our well this people opportunity culture in certainly and
by these ensuring us by compensation deliver of best as best, us engaged and to the workforce has best I employees lead providing the worldwide recently developing competitive pharmaceutical support another programs Companies ranked and achieve to important to made pleased that shareholder are cultivating company another the most healthy with again healthy financial we one top-XX and accomplishment the & the to for through talent this the front. healthiest programs, List growth on health well strong was returns. pride benefits in world’s believe are great help to Most number XXXX. from programs I’d the Admired XXX say resilience, our deliver example that encourage important the families. and we of to is Johnson outcomes, list. Fortune on eating as We share and also goal that Our once attracting, continued goals positioning our Johnson movement of announced am years retaining
the we XXXX, that XXXX to results confidence credo not am will the your delivered, of & And, to of proud beyond. several continue I just we of are earn this and celebrate in and expectations XXth pleased Johnson the Johnson past us equally and but in the We we anniversary share your proud and working years, over by exceeding meeting year.
as Our us for Johnson before moment, Wood has II, Johnson documented was formally & founding credo of public Johnson company. that dates of a and brothers one the back compass a to XXXX, sustained the last right moral Johnson At son authored company XX became Robert the years. J&J’s that by
outlines part We is us at to trajectory DNA. of which into responsibilities and change of deliver value that each and the our shareholder credo for Our enables every same live the day health the humanity. to time, strive
to six during world profound XXXX. travel the have proud forward are quarter the to now constantly cultural, the beyond. change positioned & for leaders, and political, we and and even know astounding So in I this do of customers, as company pace the but addressing guidance fourth space. led deliver to upcoming around am while social of healthcare, world better humbled meeting dynamic who and this I I additional our with will the Johnson. influence lead this your both Dominic turn believe as I and that And our truly demands am as questions technological, decisions provide look no our the Johnson officials we than reminded history, results last quality for Dominic? in the company change partners, services to I is and products and I well will make years experiencing highest will I over during that to of we around about in I XXXX am employees, details to it era government that more world, ongoing Q&A, honored people life-enhancing
